I
IOOF Investment Management Limited
+ 持有SGP
-1.16%
3個月報酬率
$28.480
+0.262 (+0.92%)收盤時
Loading chart…
- 最高
- 28.700
- 開盤
- 28.000
- 成交量加權均價
- 27.95
- 成交量
- 70.60K
- 市值
- —
- 最低
- 26.675
- 成交金額
- 1.97M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
AI 分析 of SpyGlass Pharma Inc (SGP)
買進SpyGlass Pharma, Inc. (SGP) is a good buy right now due to its recent price performance, with a current price of $28.48 and a year-to-date change of +78.00%. The RSI is at 78.57, indicating strong momentum, while the forward P/E ratio is currently at 0, suggesting potential for future earnings growth. However, the main risk is the significant net loss of $19.9 million reported in Q2 2026, which reflects ongoing expenses that could impact short-term profitability.
估值指標
SpyGlass Pharma Inc（SGP）目前預期本益比為 0.00，5 年平均預期本益比為 。
持有 SGP 的大戶
事件時間軸
資訊
9.508-19Yahoo FinanceStockland Reports 10.4% FFO Growth in Latest Earnings
4.508-14Yahoo FinanceCPI and PPI Data Spark Market Rally
9.508-06NASDAQ.COMSpyGlass Pharma Reports Wider Q2 Net Loss Amid Rising Expenses
9.505-15seekingalphaSpyGlass Pharma Reports Q1 Financial Results
- 8.503-26seekingalpha
SpyGlass Pharma Reports Q4 Earnings and IPO Details
SGP 常見問題 —— 由 Alphio AI 解答
SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye. It operates in the Healthcare sector.
SpyGlass Pharma, Inc. (SGP) is a good buy right now due to its recent price performance, with a current price of $28.48 and a year-to-date change of +78.00%. The RSI is at 78.57, indicating strong momentum, while the forward P/E ratio is currently at 0, suggesting potential for future earnings growth. However, the main risk is the significant net loss of $19.9 million reported in Q2 2026, which reflects ongoing expenses that could impact short-term profitability.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。